JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04720976. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Study identification
- NCT ID
- NCT04720976
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 58 participants
Conditions and interventions
Conditions
Interventions
- JAB-3312 Drug
- Binimetinib Drug
- Pembrolizumab Drug
- Sotorasib Drug
- Osimertinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 23, 2021 (Actual)
- Primary completion
- Dec 19, 2023 (Actual)
- Completion
- Dec 19, 2023 (Actual)
- Last update posted
- Apr 11, 2025
2021 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85054 | — |
| Research Site | Scottsdale | Arizona | 85259 | — |
| Research Site | Los Angeles | California | 90033 | — |
| Research Site | New Haven | Connecticut | 06510 | — |
| Research Site | Jacksonville | Florida | 32224 | — |
| Research Site | Orange City | Florida | 32763 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Rochester | Minnesota | 55902 | — |
| Research Site | St Louis | Missouri | 63130 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04720976, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 11, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04720976 live on ClinicalTrials.gov.